User: Guest  Login
Title:

COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy.

Document type:
Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Weckmann, Markus; Bahmer, Thomas; Sand, Jannie Marie; Rank Rønnow, Sarah; Pech, Martin; Vermeulen, Cornelis; Faiz, Alen; Leeming, Diana Julie; Karsdal, Morten Asser; Lunding, Lars; Oliver, Brian George G; Wegmann, Michael; Ulrich-Merzenich, Gudrun; Juergens, Uwe R; Duhn, Jannis; Laumonnier, Yves; Danov, Olga; Sewald, Katherina; Zissler, Ulrich; Jonker, Marnix; König, Inke; Hansen, Gesine; von Mutius, Erika; Fuchs, Oliver; Dittrich, Anna-Maria; Schaub, Bianca; Happle, Christine; Rabe, Klaus F; va...     »
Abstract:
BACKGROUND: Asthma is a heterogeneous syndrome substantiating the urgent requirement for endotype-specific biomarkers. Dysbalance of fibrosis and fibrolysis in asthmatic lung tissue leads to reduced levels of the inflammation-protective collagen 4 (COL4A3). OBJECTIVE: To delineate the degradation of COL4A3 in allergic airway inflammation and evaluate the resultant product as a biomarker for anti-IgE therapy response. METHODS: The serological COL4A3 degradation marker C4Ma3 (Nordic Bioscience, De...     »
Journal title abbreviation:
Eur Respir J
Year:
2021
Journal volume:
58
Journal issue:
6
Fulltext / DOI:
doi:10.1183/13993003.03969-2020
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/34326188
Print-ISSN:
0903-1936
TUM Institution:
611; Molekulare Allergologie (Prof. Schmidt-Weber)
 BibTeX